Ifetroban ( DrugBank: Ifetroban )

2 diseases

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	1
113	Muscular dystrophy	1

85. Idiopathic interstitial pneumonia

Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05571059 (ClinicalTrials.gov)	June 2023	27/9/2022	Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)	A Randomized, Double-Blind, Placebo-Controlled Phase II Study With an Open-Label Extension to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Idiopathic Pulmonary Fibrosis	Drug: Ifetroban Sodium;Drug: Placebo	Cumberland Pharmaceuticals	NULL	Not yet recruiting	40 Years	80 Years	All	128	Phase 2	NULL

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03340675 (ClinicalTrials.gov)	October 19, 2020	3/11/2017	Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy	A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy	Duchenne Muscular Dystrophy Cardiomyopathy;Cardiomyopathy, Dilated	Drug: Ifetroban;Drug: Placebo	Cumberland Pharmaceuticals	Vanderbilt University Medical Center	Recruiting	7 Years	N/A	Male	48	Phase 2	United States